EUVIMEDEUVIMED entdecken
Crossref

Pharmacokinetics, mass balance, and metabolism of [14C]FCN-437c, a selective and potent CDK4/6 inhibitor in humans

Lei Gao, Sheng Ma, Shu Yan, Hua Zhang, Ling Tian, Lize Li, Lei Diao, Liyan Miao, Xiaoran Yang, Xingxing Diao

Cancer Chemotherapy and Pharmacology · 2025

DOI: 10.1007/s00280-025-04779-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Chemotherapy and Pharmacology, 2025. Verfasst von Lei Gao und 9 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201210, China. Hauptthemen laut MEDLINE: Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Protein Kinase Inhibitors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Key Technologies R&D Program of Guangdong Province, National Key Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Protein Kinase InhibitorsHumansMaleAdultCarbon RadioisotopesFecesAdministration, OralYoung AdultOrganic Chemicals

Stichwörter der Autor:innen

CDK4/6 inhibitorDrug metabolismFCN-437cMass balanceRadiopharmacokinetics

Substanzen

Cyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Protein Kinase InhibitorsCarbon RadioisotopesCDK6 protein, humanCDK4 protein, humanFCN-437cOrganic Chemicals

Autor:innen und Institutionen

  • Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201210, China.
  • University of Chinese Academy of Sciences, Beijing, 100049, China.
  • First Affiliated Hospital of Soochow University, Jiangsu, 215006, China.
  • Institute for Interdisciplinary Drug Research and Translational Sciences, Soochow University, Suzhou, China.
  • Liaoning Avanc Pharmaceutical Co., Ltd., Liaoning, 121013, China.
  • Shanghai Fosun Pharmaceutical (Group) Co., Ltd, Shanghai, 200233, China.

Förderung

  • National Natural Science Foundation of China
  • Key Technologies R&D Program of Guangdong Province
  • National Key Research and Development Program of China

Zitieren

APA

Gao, L., Ma, S., Yan, S., Zhang, H., Tian, L., Li, L., Diao, L., Miao, L., Yang, X., & Diao, X. (2025). Pharmacokinetics, mass balance, and metabolism of [14C]FCN-437c, a selective and potent CDK4/6 inhibitor in humans. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-025-04779-4

Vancouver

Gao L, Ma S, Yan S, Zhang H, Tian L, Li L, et al. Pharmacokinetics, mass balance, and metabolism of [14C]FCN-437c, a selective and potent CDK4/6 inhibitor in humans. Cancer Chemotherapy and Pharmacology. 2025. doi:10.1007/s00280-025-04779-4

BibTeX
@article{Gao2025,
  author = {Gao, Lei and Ma, Sheng and Yan, Shu and Zhang, Hua and Tian, Ling and Li, Lize and Diao, Lei and Miao, Liyan and Yang, Xiaoran and Diao, Xingxing},
  title = {Pharmacokinetics, mass balance, and metabolism of [14C]FCN-437c, a selective and potent CDK4/6 inhibitor in humans},
  journal = {Cancer Chemotherapy and Pharmacology},
  year = {2025},
  doi = {10.1007/s00280-025-04779-4}
}
Kostenlos starten →